Abstract
Topiramate (TPM) is a antiepileptic drug that has multiple mechanisms of action. It
is effective as a monotherapy for migraine prophylaxis. Unfortunately, TPM can frequently
cause adverse effects, such as cognitive dysfunction. The present study examines the
neuropsychological and neurophysiological effects of TPM in 35 consecutive migraine
patients above 18 years of age. The TPM dose was started at 25 mg/day and increased by 25 mg/week, until reaching the maximum dose of 50 mg twice daily in the fourth week. Patients were evaluated for development of side
effects of the medication and for its effectiveness on migraine. The Wechsler memory
scale was used for neuropsychological evaluation and cognitive evoked potentials were
used for neurophysiologic evaluations. Analyses of repeated measures show that visual
analog scale pain values, as well as migraine attack frequency and headache duration,
were decreased significantly during the study. The amplitudes and latencies of P300
did not change. The results of this study show that 100 mg TPM is effective in the prevention of migraine headache and in reducing severity
of attacks. Patients’ cognitive complaints are frequent in the first month and decrease
in the following month. Despite these complaints, only the attention section of the
visual memory section of the Wechsler memory scale was affected – other sections were
not affected. Also, P300 study did not reflect changes appropriate to these cognitive
complaints.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Clinical NeuroscienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- AMPP advisory group. Migraine prevalence, disease burden, and the need for preventive therapy.Neurology. 2007; 68: 343-349
- Epidemiological and clinical characteristics of migraine in Sivas, Turkey.Headache. 2002; 42: 275-280
- Migraine-current understanding and treatment.N Eng J Med. 2002; 346: 257-270
- Practice parameters: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standard subcommittee of the American academy of neurology.Neurology. 2000; 55: 754-762
- Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy.Drugs. 1997; 54: 752-773
- An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action.Epilepsia. 2000; 41: S3-S9
- Topiramate effects on excitatory amino acid-mediated responses in cultured hippocampal neurons.Epilepsia. 1995; 36: S40
- Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons.Epilepsia. 2000; 41: S10-S16
- Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold.Epilepsy Res. 1997; 28: 167-179
- Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism.Epilepsia. 2000; 41: S17-S20
- Topiramate as an inhibitor of carbonic anhydrase isoenzymes.Epilepsia. 2000; 41: S35-S39
- Topiramate in migraine prevention.Expert Rev Neurotherapeutics. 2003; 3: 761-771
- Topiramate in migraine prevention: results of a large controlled trial.Arch Neurol. 2004; 61: 490-495
- Topiramate for migraine prevention – a randomized controlled trial.JAMA. 2004; 291: 965-973
- Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control.J Neurol. 2004; 251: 943-950
- Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures.Epilepsia. 1996; 37: 539-543
- Topiramate placebo controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages.Neurology. 1996; 46: 1684-1690
- Topiramate placebo controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages.Neurology. 1996; 46: 1678-1683
- Topiramate YF/YG study group. Placebo-controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial-onset epilepsy.Epilepsia. 1996; 37: 153
- Double-blind, placebo controlled study of topiramate in patients with refractory partial epilepsy.Epilepsy Res. 1996; 25: 217-224
- Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy.Epilepsia. 1996; 37: 763-768
International Headache Society. The international classification of headache disorders. 2nd ed. Cephalalgia 2004;24(Suppl. 1):1–160.
- Effects of topiramate on cognitive function.J Neurol Neurosurg Psychiatry. 2000; 69: 636-641
- Experience with topiramate monotherapy in elderly patients with recent onset epilepsy.Acta Neurol Scand. 2005; 112: 144-150
- Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy.Neurology. 2006; 67: 400-406
- A multicenter randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial onset seizures.Epilepsia. 2000; 41: 1167-1178
- Effect of topiramate on attention.Epilepsy Res. 1997; 27: 29-32
- Topiramate improves health-related quality of life when used to prevent migraine.Headache. 2005; 45: 1023-1030
- Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials.Int J Clin Pract. 2005; 59: 961-968
- Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study.Headache. 2006; 46: 642-648
- Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate.Epilepsia. 2006; 47: 695-703
Article info
Publication history
Accepted:
March 8,
2009
Received:
August 25,
2008
Identification
Copyright
© 2009 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.
